Compare BFH & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFH | EWTX |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | BFH | EWTX |
|---|---|---|
| Price | $76.11 | $22.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $65.29 | $35.89 |
| AVG Volume (30 Days) | 787.8K | ★ 1.2M |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | ★ 9.68 | N/A |
| Revenue | ★ $2,509,000,000.00 | N/A |
| Revenue This Year | $59.03 | N/A |
| Revenue Next Year | $3.92 | N/A |
| P/E Ratio | $7.83 | ★ N/A |
| Revenue Growth | ★ 1.70 | N/A |
| 52 Week Low | $38.21 | $10.60 |
| 52 Week High | $76.66 | $35.50 |
| Indicator | BFH | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 80.94 | 50.26 |
| Support Level | $73.82 | $22.77 |
| Resistance Level | $76.66 | $25.00 |
| Average True Range (ATR) | 1.83 | 1.32 |
| MACD | 0.38 | -0.40 |
| Stochastic Oscillator | 92.45 | 2.49 |
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.